Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers

Journal of Medicinal Chemistry
L Y HuG J Durant

Abstract

In the mammalian central nervous system, the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors may play an important role in brain diseases such as stroke, brain or spinal cord trauma, epilepsy, and certain neurodegenerative diseases. Compounds which specifically antagonize the actions of the neurotransmitter glutamate at the NMDA receptor ion-channel site offer a novel approach to treating these disorders. CERESTAT (4, aptiganel CNS 1102) is currently undergoing clinical trial for the treatment of traumatic brain injury and stroke. Previously, we reported that analogues of N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (4) bound to the NMDA receptor ion-channel site with high potency and selectivity. Recently, molecules active at both sigma receptors and NMDA receptor sites were investigated. A series of substituted diphenylguanidines 6 which are structurally related to N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine was prepared. Compounds containing appropriate substitution pattern in one of the phenyl rings of diphenylguanidines displayed high affinity. For example, N-(2,5-dibromophenyl)-N'-(3-ethylphenyl)-N'- methylguanidine (27b, R2 = R5 = Br, R3 = C2H5) exhibited potency at both sigma receptors and NMDA ...Continue Reading

References

Oct 1, 1986·Archives of Neurology·J T Greenamyre
Apr 27, 1988·European Journal of Pharmacology·J BénavidèsB Scatton
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·E WeberJ F Keana

❮ Previous
Next ❯

Citations

Jul 12, 2002·Journal of Neuroscience Research·Hélène HirbecJacques Vignon
May 28, 2003·Nuclear Medicine and Biology·Kjell ErlandssonLyn S Pilowsky
Dec 31, 2003·Nuclear Medicine and Biology·Rikki N Waterhouse
Jul 19, 2011·Journal of Medicinal Chemistry·Rui LiuGang Liu
Mar 5, 2002·British Journal of Clinical Pharmacology·M R WaltersK R Lees
Mar 24, 2011·Future Medicinal Chemistry·Elena ColomboPaolo Pevarello
Nov 13, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Mamoru NaruseKazutaka Higaki
Mar 30, 2007·British Journal of Clinical Pharmacology·Thomas ForstUNKNOWN CNS 5161 Study Group
Jan 10, 2012·Chemical Biology & Drug Design·Marlene Espinoza-MoragaLeonardo S Santos
Nov 3, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S K SonkusareP Ramarao
Mar 21, 2006·Nuclear Medicine and Biology·James M StoneLyn S Pilowsky
Mar 11, 2005·Expert Opinion on Emerging Drugs·Susanne D Collins, Iain P Chessell
Mar 1, 2012·Organic & Biomolecular Chemistry·Hosamani Basavaprabhu, Vommina V Sureshbabu
Dec 24, 2020·Physical Chemistry Chemical Physics : PCCP·Katherine J SchultzRyan S Renslow
Feb 15, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Colm J McGinnityJohn S Duncan
Aug 3, 2002·The Journal of Organic Chemistry·Yongping YuRichard A Houghten
Nov 13, 2001·Journal of Combinatorial Chemistry·Y YuR A Houghten
Apr 27, 2002·The Journal of Organic Chemistry·Yongping YuRichard A Houghten
Jan 13, 2004·Journal of Combinatorial Chemistry·Yongping YuRichard A Houghten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.